SCHEMBL560561

SCHEMBL560561

CCOC(=O)C(CC(=O)O)(NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.55
PTPN1 P18031 1/20 0.55
PTPRB P23467 1/20 0.55
ACP1 P24666 1/20 0.55
ALDH1A1 P00352 3/20 0.53
RECQL P46063 1/20 0.53
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HTT P42858 1/20 0.46
MMP8 P22894 1/20 0.44
SYK P43405 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560507 0.91 PTPN2 (0.54) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL560508 0.91 PTPN2 (0.54) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL560612 0.86 PTPN2 (0.56) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL560509 0.86 PTPN2 (0.56) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL560866 0.85 PTPN2 (0.58) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL3619287 0.84 PTPN2 (0.53) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL560683 0.83 ALDH1A1 (0.49) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL560684 0.83 ALDH1A1 (0.49) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL894987 0.82 PTPN2 (0.51) PTPN2PTPN1PTPRBACP1ALDH1A1
SCHEMBL560560 0.81 PTPN2 (0.53) PTPN2PTPN1PTPRBACP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434737-B2 Process for producing optically active succinimide derivatives and intermediates thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2016-09-06 US disclosed
US-20140099681-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF KYOWA HAKKO BIO CO., LTD. (JP) 2014-04-10 US disclosed
US-8633001-B2 Process for producing optically active succinimide derivatives and intermediates thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-01-21 US disclosed
US-20120034660-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF KYOWA HAKKO BIO CO., LTD. (JP) 2012-02-09 US disclosed
EP-2395097-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVE AND INTERMEDIATE THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140099681-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF SDHA, STS, DHPS PTPN2 3763/4885PTPN1 3929/4885PTPRB 2753/4885
US-20120034660-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF SDHA, STS, ALDH18A1 PTPN2 3789/4885PTPN1 4075/4885PTPRB 2727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.